Skip to main content

Grace Therapeutics, Inc.

GRCE
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001444192

In the last 90 days, Grace Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.74M in total; no superinvestor holds it.

13F holders, Q4 2022

Institutional positions in Grace Therapeutics, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
9
0 vs. Q3 2022
Shares held
50.3K
−43.0K (−46.1%) vs. Q3 2022
Total value
$24.8K
−$28.3K (−53.4%) vs. Q3 2022
New holders
3
2 more added
Sold out
3
0 more reduced

Compare with Q3 2022: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting GRCE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2022: 9 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 14 institutionsQ4 2021: 13 institutionsQ1 2022: 9 institutionsQ2 2022: 10 institutionsQ3 2022: 9 institutionsQ4 2022: 9 institutionsQ1 2023: 12 institutionsQ2 2023: 11 institutionsQ3 2023: 12 institutionsQ4 2023: 9 institutionsQ1 2024: 10 institutionsQ2 2024: 12 institutionsQ3 2024: 12 institutionsQ4 2024: 15 institutionsQ1 2025: 17 institutionsQ2 2025: 20 institutionsQ3 2025: 20 institutionsQ4 2025: 23 institutionsQ1 2026: 34 institutionsQ2 2026: 33 institutions
Value heldQ4 2022: $24.8K
Q1 2021: $0Q2 2021: $0Q3 2021: $356.5KQ4 2021: $248.8KQ1 2022: $183.7KQ2 2022: $108.2KQ3 2022: $53.1KQ4 2022: $24.8KQ1 2023: $189.6KQ2 2023: $204.2KQ3 2023: $1.55MQ4 2023: $1.65MQ1 2024: $4.34MQ2 2024: $6.30MQ3 2024: $6.36MQ4 2024: $7.84MQ1 2025: $9.17MQ2 2025: $11.3MQ3 2025: $11.0MQ4 2025: $15.0MQ1 2026: $19.7MQ2 2026: $8.74M
Institutions holding GRCE and their total value by quarter
QuarterHoldersValue
Q2 202633$8.74M
Q1 202634$19.7M
Q4 202523$15.0M
Q3 202520$11.0M
Q2 202520$11.3M
Q1 202517$9.17M
Q4 202415$7.84M
Q3 202412$6.36M
Q2 202412$6.30M
Q1 202410$4.34M
Q4 20239$1.65M
Q3 202312$1.55M
Q2 202311$204.2K
Q1 202312$189.6K
Q4 20229$24.8K
Q3 20229$53.1K
Q2 202210$108.2K
Q1 20229$183.7K
Q4 202113$248.8K
Q3 202114$356.5K
Q2 20210$0
Q1 20210$0

Institutions, Q4 2022

Shares, value and share of portfolio for each institution holding Grace Therapeutics, Inc.; share changes are against Q3 2022.

Institutions holding GRCE in Q4 2022
InstitutionSharesValue% of portfolioChange in sharesAction
Geode Capital Management, LLC18,348$9.00K0.00%00.0%Unchanged
National Bank of Canada18,418$8.86K0.00%+15,122+458.8%Added
Morgan Stanley11,295$5.66K0.00%00.0%Unchanged
Royal Bank of Canada1,706$1.00K0.00%+605+55.0%Added
Money Concepts Capital Corp187$940.00%+187New
Federation des caisses Desjardins du Quebec185$890.00%00.0%Unchanged
BlackRock Inc.62$310.00%+62New
ICA Group Wealth Management, LLC57$290.00%+57New
TD Waterhouse Canada Inc.4$30.00%00.0%Unchanged
UBS Group AG0$00.00%−24,288−100.0%Sold out
Citadel Advisors LLC0$00.00%−17,826−100.0%Sold out
Two Sigma Securities, LLC0$00.00%−16,936−100.0%Sold out